May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
A Novel Intravitreally Injectable, Crystalline Prodrug of 5–Fluorouracil (HDP–P–5f2'du) for Sustained Intraocular Drug Delivery to Treat Pathologic Intraocular Proliferation
Author Affiliations & Notes
  • Y.K. Wu
    Ophthalmology, Jacobs Retina Center at Shiley Eye Center, UCSD, La Jolla, CA
  • L. Cheng
    Ophthalmology, Jacobs Retina Center at Shiley Eye Center, UCSD, La Jolla, CA
  • K.Y. Hostetler
    Department of Medicine, San Diego Healthcare System and UCSD, La Jolla, CA
  • O. Kayikcioglu
    Ophthalmology, Jacobs Retina Center at Shiley Eye Center, UCSD, La Jolla, CA
  • N. Valiaeva
    Department of Medicine, San Diego Healthcare System and UCSD, La Jolla, CA
  • J. Beadle
    Department of Medicine, San Diego Healthcare System and UCSD, La Jolla, CA
  • G. Bergeron–Lynn
    Ophthalmology, Jacobs Retina Center at Shiley Eye Center, UCSD, La Jolla, CA
  • W.R. Freeman
    Ophthalmology, Jacobs Retina Center at Shiley Eye Center, UCSD, La Jolla, CA
  • Footnotes
    Commercial Relationships  Y.K. Wu, None; L. Cheng, None; K.Y. Hostetler, Chimerix P; O. Kayikcioglu, None; N. Valiaeva, None; J. Beadle, Chimerix P; G. Bergeron–Lynn, None; W.R. Freeman, None.
  • Footnotes
    Support  EYO 7366 (WRF)
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 471. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y.K. Wu, L. Cheng, K.Y. Hostetler, O. Kayikcioglu, N. Valiaeva, J. Beadle, G. Bergeron–Lynn, W.R. Freeman; A Novel Intravitreally Injectable, Crystalline Prodrug of 5–Fluorouracil (HDP–P–5f2'du) for Sustained Intraocular Drug Delivery to Treat Pathologic Intraocular Proliferation . Invest. Ophthalmol. Vis. Sci. 2005;46(13):471.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the intraocular properties of a newly synthesized crystalline prodrug of 5–fluorouracil (5–FU): hexadecyloxypropyl–Phospho–5–Fluro–2'–deoxyuridine (HDP–P–5F2'DU) which can be injected into the vitreous as a crystalline slurry for long acting antiproliferative intraocular therapy. Methods: HDP–P–5F2'DU was derived by adding a long carbon chain to the sugar of phospho–5–fluro–2'–deoxyuridine to achieve hydrophobic properties for intraocular drug delivery. The compound was intravitreally injected into rabbit vitreous with resultant concentrations of 5 µg/ml, 25µg/ml, 50µg/ml and 250µg/ml respectively. The toxicity and safety was evaluated with ophthalmoscopy, tonometry, electroretinography (ERG), and histopathology. Duration of action was determined by observing crystalline dissolution in vivo over time with aide of indirect ophthalmoscope. Results: Intravitreal injections of the compound revealed no clinical and pathological toxicity, compared to the controls, at all doses except for the highest dose. The highest dose caused areas of retinal and lens damage with moderate vitritis and abnormal ERGs. The other three doses demonstrated a clear vitreous and localized drug depot in the inferior vitreous cavity. The drug depot of 50µg/ml dose was observable between 8 to 10 weeks until the point of sacrifice. Conclusions: The highest non–toxic dose of the HDP–P–5F2'DU is the 50µg/ml total calculated vitreous concentration in rabbit eyes. This crystalline HDP–P–5F2'DU warrants further investigation as a long acting local therapy for unwanted intraocular proliferation.

Keywords: trauma • vitreoretinal surgery • retinal detachment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×